SEK633.50
1.17% today
Stockholm, Aug 12, 03:37 pm CET
ISIN
SE0007692850
Symbol
CAMX

Camurus Stock price

SEK641.00
-34.00 5.04% 1M
+55.00 9.39% 6M
+75.50 13.35% YTD
-29.00 4.33% 1Y
+403.00 169.33% 3Y
+477.60 292.29% 5Y
+575.00 871.21% 10Y
+575.00 871.21% 20Y
Stockholm, Closing price Mon, Aug 11 2025
-1.00 0.16%
ISIN
SE0007692850
Symbol
CAMX
Industry

Key metrics

Basic
Market capitalization
SEK38.3b
Enterprise Value
SEK35.1b
Net debt
positive
Cash
SEK3.3b
Shares outstanding
59.7m
Valuation (TTM | estimate)
P/E
53.4 | 38.6
P/S
16.9 | 14.0
EV/Sales
15.5 | 12.8
EV/FCF
56.6
P/B
9.9
Financial Health
Equity Ratio
87.6%
Return on Equity
13.0%
ROCE
21.2%
ROIC
74.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
SEK2.3b | SEK2.7b
EBITDA
SEK858.0m | SEK1.1b
EBIT
SEK838.8m | SEK1.1b
Net Income
SEK718.4m | SEK991.0m
Free Cash Flow
SEK619.8m
Growth (TTM | estimate)
Revenue
42.3% | 46.7%
EBITDA
241.0% | 126.8%
EBIT
254.3% | 125.9%
Net Income
221.8% | 131.3%
Free Cash Flow
-3.7%
Margin (TTM | estimate)
Gross
93.5%
EBITDA
37.9% | 40.3%
EBIT
37.0%
Net
31.7% | 36.2%
Free Cash Flow
27.3%
More
EPS
SEK12.0
FCF per Share
SEK10.4
Short interest
-
Employees
256
Rev per Employee
SEK7.3m
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Camurus forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Camurus forecast:

Buy
86%
Hold
14%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,267 2,267
42% 42%
100%
- Direct Costs 147 147
16% 16%
6%
2,119 2,119
45% 45%
94%
- Selling and Administrative Expenses 662 662
33% 33%
29%
- Research and Development Expense 613 613
16% 16%
27%
858 858
241% 241%
38%
- Depreciation and Amortization 19 19
29% 29%
1%
EBIT (Operating Income) EBIT 839 839
254% 254%
37%
Net Profit 718 718
222% 222%
32%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 256
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today